RecruitingACTRN12623001222639

Bacterial evolution during golden staph infections

Bacterial Adaptation during Invasive Staphylococcus aureus infections

Sponsor

University of Melbourne

Enrollment

200 participants

Start Date

May 1, 2021

Study Type

Observational

Conditions

Bone and joint infections Staphylococcus aureus infections Sepsis

Summary

BARISTA is a prospective, multi-centre bacterial genomics study of invasive Staphylococcus aureus infections that is currently recruiting the Austin Hospital and Royal Melbourne Hospital in Melbourne. Adult patients admitted for a monomicrobial sterile site infection (eg. blood, bone, or joint) are included, with up to a year follow-up. The study collects all clinical samples with growth of S. aureus (blood cultures but also bone, muscle, joint), and samples from recurrent infections within a year. Nasal swabs are collected at enrolment and after 6 and 12 months and in case of recurrence. EDTA blood is collected to extract cell-free DNA (cf-DNA).

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

Staphylococcus aureus — known as 'golden staph' — is a bacteria that can cause serious infections of the blood, bones, and joints. While antibiotics usually work, some infections come back, and the bacteria can change (evolve) over the course of treatment. Understanding how and why this happens is key to developing better treatments. The BARISTA study is collecting bacterial samples from patients admitted to Melbourne hospitals with invasive golden staph infections. By analysing the DNA of the bacteria at different points — during treatment and at follow-up — researchers can track how the bacteria evolve inside the body. Blood samples are also collected to study the body's immune response. You may be eligible if you are 18 or older, admitted to Austin Hospital or Royal Melbourne Hospital, and have a confirmed invasive S. aureus infection from a sterile site such as the bloodstream or a joint. Participation is largely observational — it involves providing additional samples alongside your regular medical care. People with polymicrobial infections (multiple types of bacteria) are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Invasive S. aureus infection (at least 1 sterile sample with growth of S. aureus [e.g. blood, valve, bone]) admitted at Austin and Royal Melbourne Hospitals in Melbourne, Victoria Following samples a

Invasive S. aureus infection (at least 1 sterile sample with growth of S. aureus [e.g. blood, valve, bone]) admitted at Austin and Royal Melbourne Hospitals in Melbourne, Victoria Following samples are collected: 1. At enrolment and during the initial admission: - all clinical samples with growth of S. aureus: blood cultures, tissue biopsies (e.g. bone, muscle), body liquids (e.g. joint fluid), pus from abscesses. These samples are already collected for clinical reasons, no additional intervention required - a nasal swab (collected by a registered nurse) - a 9 ml blood sample at enrolment, after 3 days and after 7 days (collected by a registered nurse) 2. At follow-up at 6 and 12 months after enrolment: - nasal swab (self collection) 3. At infection recurrence within 12 months: - all clinical samples with growth of S. aureus: blood cultures, tissue biopsies (e.g. bone, muscle), body liquids (e.g. joint fluid), pus from abscesses. These samples are already collected for clinical reasons, no additional intervention required - a nasal swab (collected by a registered nurse) - a 9 ml blood sample at enrolment, after 3 days and after 7 days (collected by a registered nurse)